AAPL344.82-2.29 (-0.66%) ▼|ABBV285.63-0.76 (-0.27%) ▼|ABT103.47+0.37 (+0.36%) ▲|ACN246.40+11.24 (+4.78%) ▲|ADBE248.32-0.04 (-0.02%) ▼|AMAT407.12+11.19 (+2.83%) ▲|AMD561.27+1.01 (+0.18%) ▲|AMGN452.29+4.34 (+0.97%) ▲|AMT179.01-4.83 (-2.62%) ▼|AMZN253.58+0.48 (+0.19%) ▲|AVGO345.00+2.67 (+0.78%) ▲|AXP316.40+3.49 (+1.11%) ▲|BA165.92-2.26 (-1.34%) ▼|BAC50.84+0.16 (+0.31%) ▲|BKNG148.55-1.59 (-1.06%) ▼|BLK1,146.88+10.83 (+0.95%) ▲|BMY61.01-0.55 (-0.89%) ▼|BNY148.20+0.62 (+0.42%) ▲|BRK-B543.01+0.02 (+0.00%) ▲|C123.50+0.81 (+0.66%) ▲|CAT709.64-3.67 (-0.51%) ▼|CL91.98-0.19 (-0.21%) ▼|CMCSA21.66-0.19 (-0.85%) ▼|COF204.31+0.87 (+0.43%) ▲|COP148.95+0.99 (+0.67%) ▲|COST982.90-9.23 (-0.93%) ▼|CRM243.26+2.37 (+0.98%) ▲|CSCO110.51-0.88 (-0.79%) ▼|CVS90.74-0.39 (-0.43%) ▼|CVX229.48+1.25 (+0.55%) ▲|DE642.59+3.01 (+0.47%) ▲|DHR237.13+5.13 (+2.21%) ▲|DIS109.20-1.03 (-0.93%) ▼|DUK124.62-0.19 (-0.15%) ▼|EMR167.91+1.64 (+0.99%) ▲|FDX302.00-5.10 (-1.66%) ▼|GD353.63-1.27 (-0.36%) ▼|GE297.86+0.20 (+0.07%) ▲|GEV864.11-30.97 (-3.46%) ▼|GILD160.07+0.99 (+0.62%) ▲|GM80.03-0.51 (-0.63%) ▼|GOOG320.98+4.15 (+1.31%) ▲|GOOGL324.62+4.04 (+1.26%) ▲|GS919.41+7.64 (+0.84%) ▲|HD320.83+2.33 (+0.73%) ▲|HON218.80-0.01 (0.00%) ▼|IBM252.04+1.79 (+0.72%) ▲|INTC93.26-0.48 (-0.51%) ▼|INTU333.00+4.55 (+1.39%) ▲|ISRG447.90+2.02 (+0.45%) ▲|JNJ269.83+1.10 (+0.41%) ▲|JPM337.26+1.47 (+0.44%) ▲|KO91.66+0.48 (+0.53%) ▲|LIN507.09-1.56 (-0.31%) ▼|LLY1,292.56+10.65 (+0.83%) ▲|LMT620.84-2.15 (-0.35%) ▼|LOW199.79+1.61 (+0.81%) ▲|LRCX247.76+6.91 (+2.87%) ▲|MA614.07+4.22 (+0.69%) ▲|MCD251.93+2.46 (+0.99%) ▲|MDLZ62.12-0.24 (-0.38%) ▼|MDT95.56+1.61 (+1.71%) ▲|META616.33-3.87 (-0.62%) ▼|MMM172.33+0.75 (+0.44%) ▲|MO73.31-0.18 (-0.24%) ▼|MRK141.58-0.25 (-0.17%) ▼|MS187.89+0.98 (+0.52%) ▲|MSFT529.84-1.49 (-0.28%) ▼|MU968.67+39.91 (+4.30%) ▲|NEE81.77-0.65 (-0.79%) ▼|NFLX61.87-0.65 (-1.04%) ▼|NKE37.53-0.04 (-0.09%) ▼|NOW153.52-1.26 (-0.81%) ▼|NVDA217.52-0.43 (-0.20%) ▼|ORCL130.78+0.25 (+0.19%) ▲|PEP132.45-1.05 (-0.79%) ▼|PFE29.73-0.08 (-0.25%) ▼|PG159.07-0.16 (-0.10%) ▼|PLTR195.32-3.42 (-1.72%) ▼|PM202.57-0.05 (-0.02%) ▼|QCOM183.07-1.10 (-0.60%) ▼|RTX195.30+0.70 (+0.36%) ▲|SBUX103.24+0.20 (+0.19%) ▲|SCHW88.58-0.72 (-0.81%) ▼|SO92.58-0.08 (-0.08%) ▼|SPG211.83-0.46 (-0.21%) ▼|T20.78-0.16 (-0.76%) ▼|TMO710.53+17.51 (+2.53%) ▲|TMUS145.19-1.64 (-1.12%) ▼|TSLA399.09-8.37 (-2.05%) ▼|TXN308.84-0.08 (-0.02%) ▼|UBER64.94-0.84 (-1.28%) ▼|UNH414.28+3.89 (+0.95%) ▲|UNP299.13-0.75 (-0.25%) ▼|UPS104.92-1.17 (-1.10%) ▼|USB59.61-0.13 (-0.22%) ▼|V401.52-0.34 (-0.08%) ▼|VZ43.52-0.42 (-0.94%) ▼|WFC83.44+0.78 (+0.94%) ▲|WMT118.83-0.49 (-0.41%) ▼|XOM181.67+1.76 (+0.98%) ▲|AAPL344.82-2.29 (-0.66%) ▼|ABBV285.63-0.76 (-0.27%) ▼|ABT103.47+0.37 (+0.36%) ▲|ACN246.40+11.24 (+4.78%) ▲|ADBE248.32-0.04 (-0.02%) ▼|AMAT407.12+11.19 (+2.83%) ▲|AMD561.27+1.01 (+0.18%) ▲|AMGN452.29+4.34 (+0.97%) ▲|AMT179.01-4.83 (-2.62%) ▼|AMZN253.58+0.48 (+0.19%) ▲|AVGO345.00+2.67 (+0.78%) ▲|AXP316.40+3.49 (+1.11%) ▲|BA165.92-2.26 (-1.34%) ▼|BAC50.84+0.16 (+0.31%) ▲|BKNG148.55-1.59 (-1.06%) ▼|BLK1,146.88+10.83 (+0.95%) ▲|BMY61.01-0.55 (-0.89%) ▼|BNY148.20+0.62 (+0.42%) ▲|BRK-B543.01+0.02 (+0.00%) ▲|C123.50+0.81 (+0.66%) ▲|CAT709.64-3.67 (-0.51%) ▼|CL91.98-0.19 (-0.21%) ▼|CMCSA21.66-0.19 (-0.85%) ▼|COF204.31+0.87 (+0.43%) ▲|COP148.95+0.99 (+0.67%) ▲|COST982.90-9.23 (-0.93%) ▼|CRM243.26+2.37 (+0.98%) ▲|CSCO110.51-0.88 (-0.79%) ▼|CVS90.74-0.39 (-0.43%) ▼|CVX229.48+1.25 (+0.55%) ▲|DE642.59+3.01 (+0.47%) ▲|DHR237.13+5.13 (+2.21%) ▲|DIS109.20-1.03 (-0.93%) ▼|DUK124.62-0.19 (-0.15%) ▼|EMR167.91+1.64 (+0.99%) ▲|FDX302.00-5.10 (-1.66%) ▼|GD353.63-1.27 (-0.36%) ▼|GE297.86+0.20 (+0.07%) ▲|GEV864.11-30.97 (-3.46%) ▼|GILD160.07+0.99 (+0.62%) ▲|GM80.03-0.51 (-0.63%) ▼|GOOG320.98+4.15 (+1.31%) ▲|GOOGL324.62+4.04 (+1.26%) ▲|GS919.41+7.64 (+0.84%) ▲|HD320.83+2.33 (+0.73%) ▲|HON218.80-0.01 (0.00%) ▼|IBM252.04+1.79 (+0.72%) ▲|INTC93.26-0.48 (-0.51%) ▼|INTU333.00+4.55 (+1.39%) ▲|ISRG447.90+2.02 (+0.45%) ▲|JNJ269.83+1.10 (+0.41%) ▲|JPM337.26+1.47 (+0.44%) ▲|KO91.66+0.48 (+0.53%) ▲|LIN507.09-1.56 (-0.31%) ▼|LLY1,292.56+10.65 (+0.83%) ▲|LMT620.84-2.15 (-0.35%) ▼|LOW199.79+1.61 (+0.81%) ▲|LRCX247.76+6.91 (+2.87%) ▲|MA614.07+4.22 (+0.69%) ▲|MCD251.93+2.46 (+0.99%) ▲|MDLZ62.12-0.24 (-0.38%) ▼|MDT95.56+1.61 (+1.71%) ▲|META616.33-3.87 (-0.62%) ▼|MMM172.33+0.75 (+0.44%) ▲|MO73.31-0.18 (-0.24%) ▼|MRK141.58-0.25 (-0.17%) ▼|MS187.89+0.98 (+0.52%) ▲|MSFT529.84-1.49 (-0.28%) ▼|MU968.67+39.91 (+4.30%) ▲|NEE81.77-0.65 (-0.79%) ▼|NFLX61.87-0.65 (-1.04%) ▼|NKE37.53-0.04 (-0.09%) ▼|NOW153.52-1.26 (-0.81%) ▼|NVDA217.52-0.43 (-0.20%) ▼|ORCL130.78+0.25 (+0.19%) ▲|PEP132.45-1.05 (-0.79%) ▼|PFE29.73-0.08 (-0.25%) ▼|PG159.07-0.16 (-0.10%) ▼|PLTR195.32-3.42 (-1.72%) ▼|PM202.57-0.05 (-0.02%) ▼|QCOM183.07-1.10 (-0.60%) ▼|RTX195.30+0.70 (+0.36%) ▲|SBUX103.24+0.20 (+0.19%) ▲|SCHW88.58-0.72 (-0.81%) ▼|SO92.58-0.08 (-0.08%) ▼|SPG211.83-0.46 (-0.21%) ▼|T20.78-0.16 (-0.76%) ▼|TMO710.53+17.51 (+2.53%) ▲|TMUS145.19-1.64 (-1.12%) ▼|TSLA399.09-8.37 (-2.05%) ▼|TXN308.84-0.08 (-0.02%) ▼|UBER64.94-0.84 (-1.28%) ▼|UNH414.28+3.89 (+0.95%) ▲|UNP299.13-0.75 (-0.25%) ▼|UPS104.92-1.17 (-1.10%) ▼|USB59.61-0.13 (-0.22%) ▼|V401.52-0.34 (-0.08%) ▼|VZ43.52-0.42 (-0.94%) ▼|WFC83.44+0.78 (+0.94%) ▲|WMT118.83-0.49 (-0.41%) ▼|XOM181.67+1.76 (+0.98%) ▲|
10 C
New York
Wednesday, October 28, 2026

Tag: protein

newsFORsourcecompanycontentinformation1releasesmarket

Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics

- The collaboration combines Salipro Biotech's unique expertise and its Salipro® platform technology to stabilize a challenging drug target and advance Daewoong Pharmaceutical's drug...

Growth Hormone Deficiency Market to Register Incremental Growth at a CAGR of 5.7% During the Forecast Period (2025-2034) | DelveInsight

The growth hormone deficiency market is expected to see expansion across the 7MM driven by the introduction of innovative therapies, including LUM-201 and SCO-240,...

BioAegis Therapeutics Announces US Navy Contract to Support Phase 2 Study of Recombinant Human Gelsolin, for Inflammasome-Driven Decompression Sickness (DCS)

Phase 2 proof-of-concept study for rhu-pGSN, a promising intervention across a spectrum of inflammatory diseases, to be studied as an intervention for the negative outcomes of decompression in SCUBA Divers 
Phase 2 proof-of-concept study for rhu-pGSN, a promising intervention across a spectrum of inflammatory diseases, to be studied as an intervention for the negative outcomes of decompression in SCUBA Divers

Bexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development

Bexorg Announces Multi-Program Research Collaboration with Biohaven to Enhance New CNS Drug Discovery and Development

Nutrishop Co-Founder & 75-Year-Old Father Team Up for 24th Race This Father’s Day

Father-daughter duo turns shared finish lines into a living testament that age is no barrier to wellness OLYMPIC VALLEY, Calif., June 10, 2025 /PRNewswire/ --...

Smart Healthcare Is Taking Over. Here’s Where the Money’s Headed

Issued on behalf of Avant Technologies Inc.Equity Insider News Commentary VANCOUVER, BC, June 10, 2025 /PRNewswire/ -- Both politicians and leaders in academia are touting...

Alamar Biosciences, Alzheimer’s Disease Data Initiative, and Gates Ventures Unite in Global Partnership to Advance Translational Research in Alzheimer’s Disease.

Multi-center project will profile over 40,000 samples using ultra-sensitive NULISA™ technology. FREMONT, Calif., June 10, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics...

Else Nutrition Applauds U.S. Government’s Historic Shift in Infant Formula Rules, Unlocking Path to Commercialize the World’s First Whole-Food, Dairy-Free Infant Formula

Else Nutrition Welcomes 3 Major Federal Developments that Could Unlock Market Access & Open the Door to the First Major Breakthrough in Infant Formula...

Protein Drugs Analysis Report 2025-2029: Therapeutic Proteins Gain Traction for Targeted, Low-Toxicity Treatments, Competitive Landscape Intensifies as Leading Firms Expand Investments

The Protein Drugs Market, valued at USD 441.7 billion in 2024, is set to reach USD 655.7 billion by 2029, growing at an 8.2% CAGR. The report covers market trends, technologies, regional insights, and company profiles, highlighting the rise of recombinant protein drugs for treating diseases like cancer and diabetes. 
The Protein Drugs Market, valued at USD 441.7 billion in 2024, is set to reach USD 655.7 billion by 2029, growing at an 8.2% CAGR. The report covers market trends, technologies, regional insights, and company profiles, highlighting the rise of recombinant protein drugs for treating diseases like cancer and diabetes.

HepaRegeniX Doses First Patient in Phase Ib Trial with Small Molecule Inhibitor HRX-215 to Promote Liver Regeneration

Tuebingen, Germany, June 10, 2025 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage company advancing novel therapies to treat acute and chronic liver disease, today announced that the first patient has been dosed in their Phase Ib clinical trial of its lead candidate HRX-215. The trial is evaluating the safety and efficacy of HRX-215, an orally available small-molecule inhibitor of MKK4, in patients undergoing partial liver resection due to liver metastases deriving from colorectal cancer. HXR-215 is designed to treat advanced-stage liver disease by increasing the regenerative capacity of hepatocytes. An initial data readout is planned for the second half of 2025.

Nuevocor Announces FDA Clearance of IND for NVC-001 for LMNA-Related Dilated Cardiomyopathy

LMNA-related dilated cardiomyopathy (LMNA DCM) is one of the most aggressive forms of DCM, affecting approximately 100,000 individuals in the United States and Europe,...

AMSilk enters Consumer Care Market with the launch of AMSilk4Shine and AMSilk4Care

NEURIED, Germany, 10 June 2025 /PRNewswire/ -- AMSilk, a global leader in advanced biomaterials based on silk proteins, today announces its expansion into the consumer...

Akesis Biologics Launches MastGut: A Breakthrough Supplement That Uses DUSP10 Enzyme to Support Gut and Colorectal Health

SINGAPORE, June 10, 2025 /PRNewswire/ -- Akesis Biologics, a biotechnology spin-off from the National University of Singapore (NUS), has officially launched its flagship gut...

Thirteen Studies of Ascentage Pharma’s Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress

ROCKVILLE, Md. and SUZHOU, China, June 09, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that 13 studies of its core assets - including the novel drug olverembatinib (HQP1351), the investigational Bcl-2 inhibitor lisaftoclax (APG-2575), and the investigational EED inhibitor APG-5918 – will be featured in an oral presentation, multiple poster presentations and multiple online publications at the 2025 European Hematology Association (EHA) Annual Congress taking place in Milan, Italy, from June 12-15, 2025.

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsProtein

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers